Emmaus Life Sciences

Trifecta of sickle cell disease therapies extend life expectancy, but are not cost-effective — ICER
Endpoints
Fri, 01/24/20 - 10:30 am
ICER
sickle cell disease
Novartis
Adakveo
Global Blood Therapeutics
Oxbryta
Emmaus Life Sciences
Endari
Emmaus tries to move forwards by reversing
EP Vantage
Thu, 06/13/19 - 10:06 am
Emmaus Life Sciences
Endari
sickle cell disease
Emmaus who? A biotech you never heard of just won an historic drug OK for sickle cell disease
Endpoints
Sat, 07/8/17 - 09:59 am
Emmaus Life Sciences
sickle cell disease
Emari
FDA